Skip to main content
Erschienen in: The Journal of Headache and Pain 1/2013

Open Access 01.12.2013 | Research article

Alexithymia and its impact on quality of life in a group of Brazilian women with migraine without aura

verfasst von: Rebeca Veras de Andrade Vieira, Daniel Chaves Vieira, William Barbosa Gomes, Gustavo Gauer

Erschienen in: The Journal of Headache and Pain | Ausgabe 1/2013

Abstract

Background

Migraine is a type of primary headache widely known for its impact on quality of life of patients. Although the psychological aspects of the disease are receiving increasing attention in current research, some of them, as alexithymia, are still seldom explored. This study aimed to provide evidence on the relationships between markers of depression, anxiety, alexithymia, self-reflection, insight and quality of life in migraine.

Methods

Forty female outpatients from a Brazilian specialized headache hospital service and a paired control group were compared.

Results

The results revealed that women with migraine had higher levels of depression, anxiety and alexithymia, and lower levels of quality of life, self-reflection and insight, compared to controls. Quality of life in women with migraine was predicted by levels of depression and one alexithymia factor (ability to express emotions and fantasies). A binary regression analysis between clinical and control groups revealed the migraine group to comprise individuals with high anxiety, low quality of life in the physical domain and the presence of a concrete thinking style.

Conclusions

The results highlight the relevance of considering psychological variables in the routine healthcare practices for migraine patients in general, while keeping steady attention to individual case features.
Hinweise

Competing interests

There are not conflicts of interests among the authors.

Authors’ contributions

RVAV was in charge of the recruitment of patients, data collection, data analysis, and manuscript preparation. DCV contributed with the literature review and study design. GG contributed with the study design, data analysis, discussion of results and manuscript preparation. WBG contributed with study design and manuscript preparation. All authors read and approved the final manuscript.

Background

Migraine is a type of primary headache afflicting in average 11 percent of the global adult population and approximately 15.2 percent of the Brazilian adult population [1, 2]. It is more prevalent in women than men, a pattern that can also be observed in the Brazilian population [2]. The relationship between migraine and psychological factors such as cognitive processing patterns (e.g., repetitive thinking and cognitive styles) and personality traits has received increasing attention within literature. Such research starts from the general premise that the way individuals perceive and express their ailment will have important effects in their relationship with treatment and in choosing strategies to cope with the disorder.
One of such relevant cognitive patterns is alexithymia, which is more common in migraine sufferers comparing to controls [3]. In a sample of medical students in Turkey, migraine was associated with alexithymic personality traits and comorbid psychiatric disorders [4]. There is also evidence of a positive association between alexithymia, depression and anxiety in migraine patients. Furthermore, when compared with episodic migraine patients, chronic migraine patients have significantly higher scores on measures of depression, but not alexithymia and anxiety [5]. In the same line, the relationship between alexithymia and migraine was probed in a migraine "repeaters" sample [6]. Repeaters show predominance of acute care for headache with high use and overuse of symptomatic medication [7]. The authors concluded that alexithymia and depressive mood associated with high disability may be a typical psychosocial pattern of "repeater" migraine patients.
The concept of alexithymia came about in the 1970’s, when Peter Sifneos observed peculiar characteristics in the emotional processing of psychosomatic patients [8]. Alexithymia is a multidimensional construct characterized by reduced ability to identify and describe feelings, limited capacity in engaging in fantasy or other imaginative activities, and externally-oriented thinking. It may be considered a deficit in one’s cognitive processing and regulation of emotional states [9, 10].
Apart from and psychosomatic disorders, alexithymia has also been related to intensity of pain and functional impairment in populations with medical conditions such as neuromuscular disease, diabetes, hypertension and asthma [1117]. As it interferes in the adaptive regulation of negative emotions resulting from stressing causes or psychological conflicts, alexithymia tends also to be stronger in individuals with chronic pain, such as rheumatoid arthritis, fibromyalgia, temporomandibular joint disorder and migraine [11, 18]. However, there are important individual differences in alexithymia as in the intensity of pain, as much in the population in general as in patients with chronic pain. A positive correlation between alexithymia and the intensity of acute pain is found in healthy individuals, although in patients with chronic pain alexithymia it is not necessarily related to the gravity of pain, or it has been only related to the emotional, but not the sensorial dimension of pain [18].
The association between anxiety and alexithymia has also been documented [19]. On the one hand, some authors defend that alexithymia sufferers would be more susceptible to anxiety [20]. On the other hand, there is evidence suggesting that depression or anxiety might result in a reactive regression of the emotional development and then provoke alexithymic characteristics [21].
Several studies have also supported the association between alexithymia and depression, even when alexithymia measures appear to be relatively stable accross time when compared to depression measures, suggesting they might be different constructs [2123]. However, mechanisms for the association between alexithymia and depression are not yet clear [24]. The investigation of psychiatric comorbidities in migraine has been highlighted in some studies not only because of its high impact on the individual’s quality of life but also due to the association between psychiatric comorbidities and suicide risk in those patients [2527]. Moreover, the correct assessment of depression and anxiety in migraine patients seems to play an important role for developing an adequate preventive treatment strategy, preventing the evolution of migraine into a chronic illness [28].
There are empirical evidence in literature that alexithymia might be associated with a worse quality of life. But there is no consensus among authors if this association can be observed only in some dimensions, such as the psychological or the social quality of life, or if that happens in all of its dimensions [29, 30]. Besides, some authors have found a negative correlation between satisfaction with life and alexithymia, even by taking into account confusion factors such as depression and physical health perception, which shows a possibility of low satisfaction with life being associated with difficulties in emotional processing, as is the case in alexithymia sufferers [31].
Alexithymia has been associated with other constructs related to the cognitive processing of psychic contents, such as thoughts, feelings and behaviors. For instance, self-reflection and insight were shown to be related to different psychological variables such as alexithymia, depression, anxiety and stress [32]. Self-reflection refers to the activity of inspecting and evaluating personal thoughts, sentiments and behaviors. Insight, on the other hand, concerns the state of internal understanding one has about one’s thoughts, sentiments and behaviors [33]. The self-reflection dimension has been positively correlated to anxiety and stress, but not to depression and alexithymia [32]. However, the factor insight was negatively correlated to depression, anxiety and alexithymia.
The literature still has not offered evidences about the impact of alexithymia on quality of life in migraine sufferers in the Brazilian context. There are few studies concerning possible correlations between alexithymia and depression, anxiety and other construct indicators involved in the self-monitoring of internal states such as self-reflection and insight. This study aimed at investigating the relations among the psychological factors alexithymia, self-reflection, insight, depression, anxiety; demographic variables; and aspects of the impacts of the disorder on these patients’ lives, such as severity of symptoms and quality of life in migraine sufferers as compared to a group of matched controls.

Methods

Participants

The clinical group was composed by 40 women with a migraine without aura diagnosis, according to the International Classification of Headache Disorders (2006) criteria. Participants’ age ranged from 21 to 59 years old (M = 43.58; DP = 10,71). The participants were selected among the outpatients registered at the Headache Unit of the Hospital de Clínicas de Porto Alegre (HCPA), a reference public hospital in city of Porto Alegre, state capital of Rio Grande do Sul, Brazil. The choice for evaluating exclusively women in this study is due to the profile of the population of outpatients attending the Hospital’s Headache Unit, comprising approximately 95% female.
The control group was formed by 33 women from the general population, who were receiving clinical care for other health issues than migraine, provided by general practitioners at the local public health center. Controls were paired with the clinical group by age, educational level and income status. Controls age ranged from 24 to 59 years old (M = 42.15; DP = 10,53). Some participants from the control group reported being in treatment for hypertension (7 cases), diabetes (2 cases), asthma (3 cases), labyrinthitis (1 case) and Ménièr’s Syndrome (1 case). The implications of that profile will be discussed in the last section of this article. At the public health care center, participants in the control group were questioned if they suffered of migraine or another type of headache, being excluded from the group those who presented any kind of headache, except infrequent episodic tensional headache. Participants in the clinical and control groups who met criteria for psychotic disorder or substance abuse, as screened by the instruments used in the study, were excluded.

Instruments

CAGE

It is an instrument developed to track alcohol related disorders [34]. It consists of four short questions about alcohol ingestion followed by Yes or No answers. More than one affirmative response means the participant has alcohol related problems.

Self report questionnaire

SRQ is a psychiatric disorders screening questionnaire formed by 24 questions subdivided in two sections: 20 questions aim at “neurotic” disorders detection and the remaining four questions track “psychotic” disorders [35]. The “neurotic” disorders correspond to mood, anxiety and somatoform disorders, assessed by the SCID-IV-TR (Structured Clinical Interview for DSM-IV-TR) [36].

Brazilian version of the self-reflection and insight scale

The Self-Reflection and Insight Scale consists of a self-applied questionnaire formed by 20 items participants respond to a five-point Likert scale [32]. The results of the Brazilian adaptation study revealed satisfactory internal consistency indexes, with a Cronbach’s alpha of 0.902 for the Self-reflection dimension, and 0.825 for Insight [33].

Toronto alexithymia scale

It is a self-evaluation instrument formed by 26 items, and originally idealized to measure alexithymia degrees based on four factors [37]. The validation of the Brazilian TAS version with a clinical sample of 294 general hospital patients revealed a good internal consistency, with a Cronbach’s alpha of 0.72 [38]. The author performed a factor analysis of the scale and suggested a three factors model as more adequate for clinical samples. Items in the first factor (ALEX1) were associated with the ability to identify feelings and distinguish them from bodily sensations. Items in the second factor (ALEX2) relate to a concrete thinking style. Items in the third factor (ALEX3) concern the ability to express emotion and fantasy (daydreaming). With this release of three factors, the Brazilian version of TAS for clinical population is reduced to 22 items. There are currently no established cutoff points for the Brazilian population [38].

Beck anxiety inventory

It is a self-report scale that measures the intensity of anxiety-related signals and symptoms [39]. The instrument comprises 21 descriptive affirmatives of anxiety symptoms to be evaluated by the individual in a four-point scale that reflects the gravity of each symptom. The total score is obtained by adding up the scores of the individual items. The cutoff scores for the BAI are 0–10 (minimal), 11–19 (mild), 20–30 (moderate) and 31–63 (severe). Cronbach’s alpha for BAI in clinical samples varies from 0.74 to 0.88.

Beck depression inventory

It is a self-report scale with 21 items, each one with four alternatives, related to increasing degrees of depression gravity with scores from 0 to 3 [39]. The total score is the sum of the individual scores of the items. BDI cutoff scores are 1–11 (minimal depression), 12–19 (mild depression), 20–35 (moderate depression) and 36–63 (severe depression). Cronbach’s alpha in clinical-medical samples varies from 0.77 to 0.92.

WHOQOL-BREF

The short version of World Health Organization's Quality of Life (WHOQOL-100) assesses quality of life in the physical (WHO1), psychological (WHO2), social relations (WHO3) and environmental domains (WHO4) [40]. The instrument has shown satisfactory results on discriminant validity, criterion validity, concurrent validity, and test-retest and internal consistency reliability both for the specific domains and the complete scale (WHO).

Procedure

Participants of the clinical group were found through the patients roll at the HCPA headache ambulatory between May and November, 2011. The instruments were applied in one occasion, on the same day of patients’ routine doctor’s appointment. Data collection was previously scheduled with the patients by phone and done at the Clinical Research Center. Participants in the control group were invited to participate in the study while they waited for their doctor’s appointment at the public health care center of their community. With their acceptance and after checking exclusion criteria, they were paired by age, educational level, and income to the participants of the clinical group. All the participants gave their informed consent prior to their inclusion in the study. The study received the approval by the Hospital's Institutional Review Board.

Data analysis

The data matrix was inspected and the missing values were substituted by the average value of the case in the respective variable. Descriptive statistics were performed for the sociodemographic data for the total participants, as well as for the control and clinical groups in separate. Inferential statistics were also run for groups and overall sample (Chi-squared test, student’s t-test, Pearson correlation, analysis of covariance, multiple regression analysis, binary logistic regression), using SPSS (Statistical Package for Social Sciences), and adopting a 5% significance level.

Results

Sociodemographic characteristics of the sample are shown at Table 1. Significant differences regarding those features between the control and clinical groups were not found. The same table features the values of duration of disease in months (DD), duration of treatment in months (DT), pain frequency in the last three months in days (PF) and an average grade attributed by the participants to their pain in the last three months in a scale ranging from 0–10 (PG) for the clinical group are described. To evaluate the grade attributed to the pain (PG) and the frequency of pain (FP) the authors used two questions from the Migraine Disability assessment Scale-MIDAS [41], a widely used measure of headache-related disability in migraine. The questions were "On how many days in the last 3 months did you have a headache?" and "On a scale of 0 to 10, on average how painful were these headaches? (where 0 = no pain at all and 10 = pain as bad as it can be".
Table 1
Sociodemographic characteristics of the sample
Variables
Control group
Clinical group
Total
Age: Mean (SD)
42,15 (10,53)
43,58 (10,71)
42,93 (10,58)
Range
24-59
21-59
21-59
Educational
Elementary = 14 (42,4)
Elementary = 20 (50)
Elementary = 34 (46,6)
Level: f (%)
High school = 11 (33,3)
High School = 12 (30)
High School = 23 (31,5)
Professional = 3 (9,1)
Professional = 3 (7,5)
Professional = 6 (8,2)
College = 5 (15,2)
College = 5 (12,5)
College = 10 (13,7)
Outcome (in current minimum wages): f (%)
Until 1 = 0 (0)
Until 1 = 2 (5)
Until 1 = 2 (2,7)
From 1 to 3 = 22 (66,7)
From 1 to 3 = 24 (60)
From 1 to 3 = 46 (63)
From 3 to 5 = 10 (30,3)
From 3 to 5 = 11 (27,5)
From 3 to 5 = 21 (28,8)
From 5 to 10 = 1 (3)
From 5 to 10 = 3 (7,5)
From 5 to 10 = 4 (5,5)
Marital status: f (%)
Married = 14 (42,4)
Married = 19 (47,5)
Married = 33 (45,2)
Divorced =5 (15,2)
Divorced = 6 (15)
Divorced = 11 (15,1)
Single = 11 (33,3)
Single =13 (32,5)
Single = 24 (32,9)
Widowed = 3 (9,1)
Widowed = 2 (5)
Widowed = 5 (6,8)
DD: M (SD)
 
242,10 (152,15)
 
Range
 
36-564
 
DT: M (SD)
 
57,52 (65,28)
 
Range
 
3-312
 
PF: M (SD)
 
27,65 (25,00)
 
Range
 
0-90
 
PG: M (SD)
 
8,03 (2,14)
 
Range
 
0-10
 
SD = standard deviation, f = frequency, % = percentage.
A comparison among the average levels of the variables investigated in the present study is shown at Table 2. Significant differences were observed in all variables between the control and clinical groups. The effect size of those differences ranged from d = 0.56 to 1.41, showing that the groups presented very different profiles regarding such variables.
Table 2
Dependent variables means in the clinical and control groups and group comparisons
Variables
Mean (SD); Range
Control group
Clinical group
Total
t value; Cohen's d
BDI
8,33(8,69);0-37
16,70(10,17);1-49
12,92(10,35) 0-49
t = −3,73 (71); p < 0,001; d = 0,88
BAI
6,18(7,46) 0-25
19,73(12,69) 0-51
13,60(12,57) 0-51
t = −5,67 (64,68); p < 0,001; d = 1,41
WHOQOL
95,79(12,35) 59-127
82,20(15,33) 50-112
88,34(15,54) 50-127
t = 4,19 (70,97); p < 0,001; d = 0,99
WHOQOL1
27,06(3,74) 16-35
21,39(4,65) 11-33
23,95(5,10) 11-35
t = 5,67 (71); p < 0,001; d = 1,34
WHOQOL2
22,73(3,25) 14-30
19,97(4,37) 9-28
21,22(4,12) 9-30
t = 3,08 (70,32); p = 0,003; d = 0,73
WHOQOL3
11,61(2,16) 8-15
9,90(2,38) 4-14
10,67(2,43) 4-15
t = 3,17(71); p = 0,002; d = 0,75
WHOQOL4
27,33(4,37) 16-28
24,73(4,89) 11-33
25,90(4,81) 11-38
t = 2,38 (71); p = 0,02; d = 0,56
ALEXITHYMIA
53,21(9,49) 32-70
63,72(8,30) 50-89
58,97(10,25) 32-89
t = −5,05 (71); p < 0,001; d = 1,20
ALEX1
26,30(7,70) 11-42
32,28(7,82) 15-50
29,58(8,27) 11-50
t = −3,27 (71); p = 0,002; d = 0,78
ALEX2
16,09(4,57) 9-30
19,30(5,46) 7-33
17,85(5,29) 7-33
t = −2,69 (71); p = 0,009; d = 0,64
ALEX3
10,82(2,20) 7-17
12,15(2,52) 5-17
11,55(2,45) 5-17
t = −2,38 (71); p = 0,02; d = 0,56
SR
32,64(7,24) 14-46
28,88(5,43) 13-40
30,58(6,55) 13-46
t = 2,53 (71); p = 0,01; d = 0,60
INS
21,39(5,75) 9-29
16,33(6,14) 5-29
18,62(6,45) 5-29
t = 3,61 (71); p = 0,001; d = 0,86
SD = standard deviation; SR: Self-reflection; INS: Insight.
Table 3 shows bivariate correlations between the investigated variables, also including the sociodemographic variables of the studies for the control and clinical groups. Table 4 features associations among the following variables: duration of disease (DD), duration of treatment (DT), pain frequency in the last three months in days (PF) and an average grade attributed by the participants to their pain in the last three months in a scale ranging from 0–10 (PG) with the other variables. Association between pain frequency (in days) in the last three months (PF), variables related to mental health (depression and anxiety) and quality of life (total and in the physical, psychological and environmental domains) can be observed. The duration of disease (DD) presented a positive association with the age of the participants, while the variable average score attributed by the participants to their pain in the last three months (PG) was positively associated to anxiety levels and negatively to insight capacity.
Table 3
Bivariate correlations between investigated variables
Variável
Control group / Clinical group a
 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
1-BDI
-
0,61**
−0,76**
−0,67**
−0,77**
−0,52**
−0,64**
0,40*
0,40*
0,01
0,06
−0,23
−0,41**
0,19
−0,09
−0,08
2-BAI
0,62**
-
−0,49**
−0,51**
−0,45**
−0,11
−0,43**
0,22
0,41**
−0,23
−0,04
0,20
−0,54**
0,27
−0,15
−0,06
3-WHOQOL
−0,72**
−0,59**
-
0,91**
0,91**
0,69**
0,86**
−0,42**
−0,23
−0,18
−0,30
0,265
0,34*
−0,18
−0,11
0,02
4-WHOQOL1
−0,60**
−0,68**
0,83**
-
0,79**
0,53**
0,66**
−0,41**
−0,23
−0,19
−0,26
0,25
0,48**
−0,29
−0,05
−0,02
5-WHOQOL2
−0,58**
−0,31
0,87**
0,61**
-
0,53**
0,69**
−0,38*
−0,26
−0,15
−0,11
0,31*
0,37*
−0,09
−0,09
0,04
6-WHOQOL3
−0,50**
−0,30
0,68**
0,48**
0,73**
-
0,60**
−0,28
−0,05
−0,23
−0,27
0,16
0,00
−0,08
−0,10
−0,07
7-WHOQOL4
−0,57**
−0,44*
0,84**
0,56**
0,64**
0,41*
-
−0,36*
−0,155
−0,14
−0,38*
0,20
0,18
−0,06
−0,06
0,12
8-ALEXITHYMIA
0,41*
0,41*
−0,64**
−0,53**
−0,54**
−0,36*
−0,63**
-
0,70**
0,46**
0,11
−0,20
−0,58**
0,04
0,23
0,08
9-ALEX-1
0,60**
0,47**
−0,63**
−0,56**
−0,48**
−0,38*
−0,59**
0,80**
-
−0,24
−0,26
0,15
−0,64**
0,17
−0,01
0,12
10-ALEX2
−0,06
0,10
−0,22
−0,11
−0,28
−0,12
−0,21
0,61**
0,05
-
0,09
−0,49**
−0,03
−0,13
0,25
−0,12
11-ALEX3
−0,21
−0,09
−0,09
−0,07
−0,05
0,04
−0,18
0,26
−0,17
0,36*
-
−0,07
0,13
−0,12
0,25
0,13
12-SR
−0,31
−0,39
0,20
0,31
−0,04
−0,07
0,23
−0,34*
−0,28
−0,20
−0,11
-
−0,01
−0,11
0,00
0,21
13-INS
−0,72**
−0,56**
0,63**
0,57**
0,44*
0,52**
0,53**
−0,58**
−0,72**
−0,07
0,17
0,30
-
−0,20
0,11
0,00
14-Age
−0,17
−0,09
0,20
−0,02
0,21
0,11
0,43*
−0,21
−0,29
−0,03
0,19
0,20
0,09
-
−0,15
0,07
15-Education
−0,04
−0,09
0,05
0,01
0,01
−0,11
0,14
−0,05
−0,03
−0,01
−0,09
0,20
0,01
−0,08
-
0,41**
16-Outcome
0,04
0,14
−0,04
−0,07
−0,06
−0,19
0,13
−0,04
−0,15
0,19
−0,05
0,26
−0,03
0,02
0,65**
-
aLower diagonal refers to the control group; upper diagonal represents the clinical group. *p <0,05; **p < 0,01.
Table 4
Correlations between specific variables in the clinical group
Variables
DD
DT
PF
PG
TL
0,21
   
PF
−0,04
0,01
  
PG
0,08
0,02
0,20
 
BDI
0,18
0,24
0,45**
0,14
BAI
0,11
0,01
0,50**
0,37*
WHOQOL
−0,20
−0,19
−0,45**
0,00
WHOQOL1
−0,16
−0,04
−0,51**
−0,10
WHOQOL2
−0,11
−0,22
−0,43**
0,04
WHOQOL3
−0,13
−0,22
−0,21
0,23
WHOQOL4
−0,19
−0,22
−0,32*
−0,01
ALEXITHYMIA
0,08
−0,08
0,11
0,26
ALEX1
0,20
−0,02
−0,07
0,30
ALEX2
−0,15
−0,17
0,16
0,08
ALEX3
−0,02
0,02
0,24
−0,24
SR
−0,20
−0,13
−0,13
0,00
INS
−0,22
0,13
−0,25
−0,32*
AGE
0,42**
0,11
0,07
0,08
EDUCATION
−0,07
0,12
−0,09
−0,30
OUTCOME
−0,06
−0,08
−0,01
−0,14
*p < 0,05; **p < 0,01.
Considering the associations among variables described in Table 4, ANCOVAs were performed with the purpose of investigating differences between the control and clinical groups, controlling the co-variables effect. The co-variables considered in each model were those that presented significant associations with the dependent variable. Only the variables total alexithymia and anxiety kept differences between the groups after control of the shared variance with the other variables. So, the fact of belonging to the control or to the clinical groups explains, respectively, 10% and 12% of the variance of these variables.
Table 5 shows a multiple linear regression analysis identifying predictors of quality of life for each group and for the total sample. It also depicts those variables predicting pain frequency (in days) in the last three months (PF) for the clinical group. This analysis evidences that depression, anxiety and alexithymia have predictive power over quality of life in general and its domains for the total, control and clinical groups. Regarding specifically the clinical group, pain frequency (PF) was predicted by the variables anxiety and ALEX1.
Table 5
Linear regression models for quality of life and pain frequency (in days) in the last three months (PF)
Sample
Variable
Predictors*
B
Beta
Adjusted
Total
WHO
BDI
−1,13
−0,76
0,70
  
Alex3
−1,35
−0,21
 
  
Alex2
−0,48
−0,16
 
 
WHO1
BDI
−0,22
−0,44
0,65
  
BAI
−0,14
−0,36
 
  
Alex3
−0,39
−0,19
 
  
Alex2
−0,17
−0,18
 
 
WHO2
BDI
−0,28
−0,72
0,57
  
Alex2
−0,15
−0,19
 
 
WHO3
BDI
−0,13
−0,56
0,37
  
Alex2
−0,10
−0,21
 
 
WHO4
BDI
−0,29
−0,63
0,50
  
Alex3
−0,61
−0,31
 
Control
WHO
BDI
−1,04
−0,73
0,55
  
Alex2
−0,71
−0,26
 
  
BAI
−0,27
−0,53
0,51
  
Alex1
−0,15
−0,31
 
 
WHO2
BDI
−0,22
−0,59
0,39
  
Alex2
−0,22
−0,31
 
 
WHO3
Ins
0,20
0,52
0,25
 
WHO4
Alex1
−0,23
−0,41
0,49
  
Alex3
−0,68
−0,34
 
  
BDI
−0,20
0,40
 
Clinical
WHO
BDI
−1,12
−0,75
0,62
  
Alex3
−1,54
−0,25
 
 
WHO1
BDI
−0,31
−0,67
0,44
 
WHO2
BDI
−0,33
−0,77
0,58
 
WHO3
BDI
−0,12
−0,52
0,25
 
WHO4
BDI
−0,30
−0,62
0,50
  
Alex3
−0,67
−0,34
 
Clinical
PF
BAI
1,23
0,63
0,30
  
Alex1
−1,04
−0,33
 
* Predictors with a significance level ≤ 0.05 by stepwise estimation method.
Finally, a binary logistic regression analysis (depicted in Table 6) revealed that the variables that better distinguish the control and clinical groups are related to anxiety, the physical domain of quality of life (WHO1) and concrete thinking style, based on reality, without imagination and fantasy (ALEX2). The model reached a satisfactory level of correct classification of the cases, of 85%, proving adequate to predict belonging to the respective groups.
Table 6
Variables predicting pertinence to the clinical group
  
Binary logistic regression analysis
  
Predictors*
B (e.p.)
Wald(gl)
Odds ratio
Correct classification 85%
Total
Group
BAI
0,11
6,12
1,11
 
  
WHO1
−0,16
2,68
0,85
 
  
Alex2
0,17
4,96
1,18
 
* Predictors with a significance level ≤ 0.05 by stepwise estimation method.
Omnibus = 5,81(1), p = 0,02; Hosmer-Lemeshow = 16,85(8), p = 0,03.

Discussion

The lack of correlation between alexithymia and sociodemographic variables (age, income and educational level) goes against discoveries of other studies [42, 43]. This might be due to the small size and relative homogeneity of the sample in this study for both groups. However, regarding the group of migraine sufferers, a lack of co-relation between alexithymia and sociodemographic variables was also found in a Turkish sample, which points towards a possible specificity in the grouping form of these variables in the migraine sufferers group [3].
Migraine sufferers have shown higher levels of depression, anxiety and alexithymia, and lower levels of quality of life, self-reflection and insight, compared to a group of matched controls. The statistical significance of those differences corroborates the empirical relevance of such variables in investigating migraine in what characterizes the diagnosed sufferers. Besides, showing high distinction for migraine comparing to the control group, the relevance is stressed by the fact that the same variables have not shown significant results, in terms of correlation, interaction or distinction between groups, with none of the sociodemographic data.
The scores for total alexithymia correlated negatively with self-reflection and insight for the total sample and the control group as well. However, in the clinical group the total score for alexithymia only correlated negatively with insight and not with self-reflection. This lack of correlation between alexithymia and self-reflection subscribes previous findings from a non-clinical sample [32].
Discussion of the current data requires resorting to conceptual matters. Alexithymia concerns incapacity or difficulty to express emotions through words. Insight refers to the individual capability of understanding one’s own thoughts, feelings and behaviors. Self-reflection is the individual practice of inspection and evaluation of one’s own thoughts, feelings and behaviors. Sensibility in perceiving internal states and the construct related to one’s understanding of these states (insight) are certainly associated with the capability of understanding and expressing feelings [32]. Insight, in particular, predicts several emotion and self-evaluation markers: individuals with higher insight have a better functioning on this kind of capability, and insight predicts well-being markers [44].
In the case of migraine sufferers of the present study, there might be cognitive information processing regarding internal states in some degree. However, since the correlation direction expected and found in the control group would be negative, it is possible that migraine disorder associated with a type of chronic pain that “seizes” the patient and is hard to manage because of its unpredictability makes sufferers effectively have a forced self-reflection practice. This self-reflection would be a perception of one’s internal states, such as paying attention to the pain during a crisis and its possible internal or environmental triggers.
A reason to evaluate self-reflection and insight in clinical groups is their potential application in contexts where attention and introspection abilities focusing on internal states are able to predict the success of interventions [44]. In the case of migraine, the abilities of this field might constitute either resources or limiting features of important aspects of pain and treatment management, such as observing crisis triggers and evaluating medication effects.
Pain frequency in the last three months (PF) was significantly correlated to depression, anxiety and total quality of life and in the physical, psychological and social domains. This result stresses the strength of approximation of these variables in migraine, even if it is not possible to draw casualty directions in this study because of its transversal character. The average grade attributed by participants to their pain in the last three months (PG) was negatively correlated to insight and positively to anxiety. Perception and subjective evaluation of pain might have been influenced in these individuals by their loss of insight capability. In this way, insight might be interpreted as a cognitive mediator between perception and expression of pain, with specific effect, because of its interaction with alexithymia in the case of migraines. Alexithymia is indeed reposted in literature as an increase factor for sensitivity to pain and more somatic complaints [45].
There remains the question of whether elevated somatic complaints, higher sensitivity and lower pain tolerance in correlation to alexithymia could generate a model or an operationalization of the mechanisms through which migraine-related information is processed. Perhaps alexithymia, as a phenomenon of having difficulty expressing feelings, is closer to an outcome function of a process starting with self-reflection as a perception of one’s internal states, continuing with insight as a quality of cognitive data processing, supporting the individual’s reasoning processes over causes and effects of their illness.
The logistic regression analysis indicated two alexithymia dimensions (ALEX2 and ALEX3) and depression as predictors of quality of life in the total sample. However, comparing the clinical and control groups, each one of those same alexithymia dimensions related to a specific predictor. In the migraine sufferers group, quality of life (WHO) had as predictor, with negative charge, the capability in expressing emotions and fantasies (ALEX3), and in the control group, a concrete thinking style, without imagination and fantasies (ALEX2). This result is interesting because it relates quality of life in migraine sufferers to the possibility of expressing emotion and fantasy, reinforcing the importance of developing spaces to express sickness and treatment representations.
In the clinical group, pain frequency in the last three months (PF) was predicted by the variables anxiety and ability in identifying and describing feelings and distinguishing them from bodily sensations (ALEX1). This might happen because these variables are related to one of the main triggers described in literature: emotional stress.
In the binary logistic regression analysis, the Hosmer-Lemeshow index suggested discrepancies between the observed and predicted classifications, meaning that 15 percent of the cases were classified wrongly by the model. That might have happened because the control group is formed by individuals recruited in the primary health care network, who frequently have other disorders (hypertension, diabetes and asthma) which are frequently associated with alexithymic traits [4650]. However, this lack of “purity” in the control group along with the significant difference of averages in all variables (alexithymia, self-reflection, insight, depression, anxiety and quality of life) reinforces the distinction between migraine sufferers and non-sufferers and the importance of the assessment of those variables in migraine patients. On the other hand, by making an analysis inside the clinical group, one can perceive a broad variability in every one of the variables, which corroborates the idea of intragroup heterogeneity among migraine sufferers.
The binary regression analysis of the division variable of both clinical and control groups revealed that migraine might characterize individuals with high anxiety, low quality of life in the physical domain (WHO1), and presence of a concrete thinking style, without imagination and fantasies (ALEX2). These results indicate the importance of evaluating these features during the routine medical appointment and planning adequate therapeutics aiming to decrease anxiety and developing symbolization capacity in migraine sufferers.

Conclusions

This study demonstrated that migraine sufferers presented higher levels of depression, anxiety and alexithymia, and lower levels of quality of life, self-reflection and insight, comparing to control groups. However seeming two completely different groups, there is a high variability in all variables studied inside each group, which shows an intragroup heterogeneity. Hence, the results reinforce that while such variables present themselves as relevant in migraine sufferers, health professionals must evaluate them in their daily practice, watching attentively every individual case.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Competing interests

There are not conflicts of interests among the authors.

Authors’ contributions

RVAV was in charge of the recruitment of patients, data collection, data analysis, and manuscript preparation. DCV contributed with the literature review and study design. GG contributed with the study design, data analysis, discussion of results and manuscript preparation. WBG contributed with study design and manuscript preparation. All authors read and approved the final manuscript.
Literatur
1.
Zurück zum Zitat Stovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton RB, Scher AI, Steiner TJ, Zwart J-A: The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007,27(3):193–210. 10.1111/j.1468-2982.2007.01288.xPubMedCrossRef Stovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton RB, Scher AI, Steiner TJ, Zwart J-A: The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007,27(3):193–210. 10.1111/j.1468-2982.2007.01288.xPubMedCrossRef
2.
Zurück zum Zitat Queiroz LP, Peres MFP, Piovesan EJ, Kowacs F, Ciciarelli MC, Souza JA, Zukerman E: A nationwide population-based study of migraine in Brazil. Cephalalgia 2009,29(6):642–649. 10.1111/j.1468-2982.2008.01782.xPubMedCrossRef Queiroz LP, Peres MFP, Piovesan EJ, Kowacs F, Ciciarelli MC, Souza JA, Zukerman E: A nationwide population-based study of migraine in Brazil. Cephalalgia 2009,29(6):642–649. 10.1111/j.1468-2982.2008.01782.xPubMedCrossRef
3.
Zurück zum Zitat Muftuoglu MN, Herken H, Demirci H, Virit O, Neyal A: Alexithymic features in migraine patients. Eur Arch Psychiatry Clin Neurosci 2004, 254: 182–186.PubMed Muftuoglu MN, Herken H, Demirci H, Virit O, Neyal A: Alexithymic features in migraine patients. Eur Arch Psychiatry Clin Neurosci 2004, 254: 182–186.PubMed
4.
Zurück zum Zitat Balaban H, Semiz M, Sentürk IA, Kavakç Ö, Çmar Z, Dikici A, Topaktas S: Migraine prevalence, alexithymia, and post-traumatic stress disorder among medical students in Turkey. J Headache Pain 2012,13(6):459–467. 10.1007/s10194-012-0452-7PubMedCentralPubMedCrossRef Balaban H, Semiz M, Sentürk IA, Kavakç Ö, Çmar Z, Dikici A, Topaktas S: Migraine prevalence, alexithymia, and post-traumatic stress disorder among medical students in Turkey. J Headache Pain 2012,13(6):459–467. 10.1007/s10194-012-0452-7PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Yalug I, Selekler M, Erdogan A, Kutlu A, Dundar G, Ankarali H, Aker T: Correlations between alexithymia and pain severity, depression, and anxiety among patients with chronic and episodic migraine. Psychiatry Clin Neurosci 2010,64(3):231–238. 10.1111/j.1440-1819.2010.02093.xPubMedCrossRef Yalug I, Selekler M, Erdogan A, Kutlu A, Dundar G, Ankarali H, Aker T: Correlations between alexithymia and pain severity, depression, and anxiety among patients with chronic and episodic migraine. Psychiatry Clin Neurosci 2010,64(3):231–238. 10.1111/j.1440-1819.2010.02093.xPubMedCrossRef
6.
Zurück zum Zitat Villani V, Bruti G, Mostardini C, Di Stani F, Scattoni L, Dugoni D, Vanacore N, Cerbo R: Migraine in the Emergency Department: a psychometric study of a migraine "repeaters" sample. J Headache Pain 2005,6(4):301–303. 10.1007/s10194-005-0214-xPubMedCentralPubMedCrossRef Villani V, Bruti G, Mostardini C, Di Stani F, Scattoni L, Dugoni D, Vanacore N, Cerbo R: Migraine in the Emergency Department: a psychometric study of a migraine "repeaters" sample. J Headache Pain 2005,6(4):301–303. 10.1007/s10194-005-0214-xPubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Maizels M: Health resource utilization of the emergency department headache “repeater”. Headache 2002, 42: 1026–1031. Maizels M: Health resource utilization of the emergency department headache “repeater”. Headache 2002, 42: 1026–1031.
8.
Zurück zum Zitat Sifneos PE: The prevalence of “alexithymic” characteristics in psychosomatic patients. Psychother Psychosom 1973,22(2):255–262. 10.1159/000286529PubMedCrossRef Sifneos PE: The prevalence of “alexithymic” characteristics in psychosomatic patients. Psychother Psychosom 1973,22(2):255–262. 10.1159/000286529PubMedCrossRef
9.
Zurück zum Zitat Luminet O, Rime B, Bagby M, Taylor GJ: A multimodal investigation of emotional responding in alexithymia. Cogn Emot 2004,18(6):741–766. 10.1080/02699930341000275CrossRef Luminet O, Rime B, Bagby M, Taylor GJ: A multimodal investigation of emotional responding in alexithymia. Cogn Emot 2004,18(6):741–766. 10.1080/02699930341000275CrossRef
10.
Zurück zum Zitat Taylor GJ, Bagby RM: New trends in alexithymia research. Psychother Psychosom 2004,73(2):68–77. 10.1159/000075537PubMedCrossRef Taylor GJ, Bagby RM: New trends in alexithymia research. Psychother Psychosom 2004,73(2):68–77. 10.1159/000075537PubMedCrossRef
11.
Zurück zum Zitat Hosoi M, Molton IR, Jensen MP, Ehde DM, Amtmann S, O'Brien S, Arimura T, Kubo C: Relationships among alexithymia and pain intensity, pain interference, and vitality in persons with neuromuscular disease: Considering the effect of negative affectivity. Pain 2010,149(2):273–277. 10.1016/j.pain.2010.02.012PubMedCentralPubMedCrossRef Hosoi M, Molton IR, Jensen MP, Ehde DM, Amtmann S, O'Brien S, Arimura T, Kubo C: Relationships among alexithymia and pain intensity, pain interference, and vitality in persons with neuromuscular disease: Considering the effect of negative affectivity. Pain 2010,149(2):273–277. 10.1016/j.pain.2010.02.012PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Vazquez I, Sández E, González-Freire B, Romero-Frais E, Blanco-Aparicio M, Verea-Hernando H: The role of alexithymia in quality of life and health care use in asthma. J Asthma 2010,47(7):797–804. 10.3109/02770900903560217PubMedCrossRef Vazquez I, Sández E, González-Freire B, Romero-Frais E, Blanco-Aparicio M, Verea-Hernando H: The role of alexithymia in quality of life and health care use in asthma. J Asthma 2010,47(7):797–804. 10.3109/02770900903560217PubMedCrossRef
13.
Zurück zum Zitat Chung MC, Rudd H, Wall N: Posttraumatic stress disorder following asthma attack (post-asthma attack PTSD) and psychiatric co-morbidity: the impact of alexithymia and coping. Psychiatry Res 2012,197(3):246–252. 10.1016/j.psychres.2012.01.008PubMedCrossRef Chung MC, Rudd H, Wall N: Posttraumatic stress disorder following asthma attack (post-asthma attack PTSD) and psychiatric co-morbidity: the impact of alexithymia and coping. Psychiatry Res 2012,197(3):246–252. 10.1016/j.psychres.2012.01.008PubMedCrossRef
14.
Zurück zum Zitat Chatzi L, Bitsios P, Solidaki E, Christou I, Kyrlaki E, Sfakianaki M, Kogevinas M, Kefalogiannis N, Pappas AJ: Type 1 diabetes is associated with alexithymia in nondepressed, non-mentally ill diabetic patients: a case–control study. Psychosom Res 2009,67(4):307–313. 10.1016/j.jpsychores.2009.04.011CrossRef Chatzi L, Bitsios P, Solidaki E, Christou I, Kyrlaki E, Sfakianaki M, Kogevinas M, Kefalogiannis N, Pappas AJ: Type 1 diabetes is associated with alexithymia in nondepressed, non-mentally ill diabetic patients: a case–control study. Psychosom Res 2009,67(4):307–313. 10.1016/j.jpsychores.2009.04.011CrossRef
15.
Zurück zum Zitat Luminet O, de Timary P, Buysschaert M, Luts A: The role of alexithymia factors in glucose control of persons with type 1 diabetes: a pilot study. Diabetes Metab 2006,32(5):417–424. 10.1016/S1262-3636(07)70299-9PubMedCrossRef Luminet O, de Timary P, Buysschaert M, Luts A: The role of alexithymia factors in glucose control of persons with type 1 diabetes: a pilot study. Diabetes Metab 2006,32(5):417–424. 10.1016/S1262-3636(07)70299-9PubMedCrossRef
16.
Zurück zum Zitat Rafanelli C, Offidani E, Gostoli S, Roncuzzi R: Psychological correlates in patients with different levels of hypertension. Psychiatry Res 2012,198(1):154–160. 10.1016/j.psychres.2011.09.014PubMedCrossRef Rafanelli C, Offidani E, Gostoli S, Roncuzzi R: Psychological correlates in patients with different levels of hypertension. Psychiatry Res 2012,198(1):154–160. 10.1016/j.psychres.2011.09.014PubMedCrossRef
17.
Zurück zum Zitat Jula A, Salminen JK, Saarijärvi S: Alexithymia: a facet of essential hypertension. Hypertension 1999,33(4):1057–1061. 10.1161/01.HYP.33.4.1057PubMedCrossRef Jula A, Salminen JK, Saarijärvi S: Alexithymia: a facet of essential hypertension. Hypertension 1999,33(4):1057–1061. 10.1161/01.HYP.33.4.1057PubMedCrossRef
18.
Zurück zum Zitat Lumley MA, Radcliffe AM, Macklem DJ, Mosley-Williams A, Leisen JCC, Huffman JL, D’Souza PJ, Gillis ME, Meyer TM, Kraft CA, Rapport LJ: Alexithymia and Pain in Three Chronic Pain Samples: Comparing Caucasians and African Americans. Pain Med 2005, 6: 251–261. 10.1111/j.1526-4637.2005.05036.xPubMedCrossRef Lumley MA, Radcliffe AM, Macklem DJ, Mosley-Williams A, Leisen JCC, Huffman JL, D’Souza PJ, Gillis ME, Meyer TM, Kraft CA, Rapport LJ: Alexithymia and Pain in Three Chronic Pain Samples: Comparing Caucasians and African Americans. Pain Med 2005, 6: 251–261. 10.1111/j.1526-4637.2005.05036.xPubMedCrossRef
19.
Zurück zum Zitat Marchesi C, Fontò S, Balista C, Cimmino C, Maggini C: Relationship between alexithymia and panic disorder: a longitudinal study to answer an open question. Psychother Psychosom 2005, 74: 56–60. 10.1159/000082028PubMedCrossRef Marchesi C, Fontò S, Balista C, Cimmino C, Maggini C: Relationship between alexithymia and panic disorder: a longitudinal study to answer an open question. Psychother Psychosom 2005, 74: 56–60. 10.1159/000082028PubMedCrossRef
20.
Zurück zum Zitat Devine H, Stewart SH, Watt MC: Relations between anxiety sensitivity and dimensions of alexithymia in a young adult sample. J Psychosom Res 1999, 47: 145–158. 10.1016/S0022-3999(99)00033-1PubMedCrossRef Devine H, Stewart SH, Watt MC: Relations between anxiety sensitivity and dimensions of alexithymia in a young adult sample. J Psychosom Res 1999, 47: 145–158. 10.1016/S0022-3999(99)00033-1PubMedCrossRef
21.
Zurück zum Zitat Honkalampi K, Hintikka J, Saarinen P, Lehtonen J, Viinamaki H: Is alexithymia a permanent feature in depressed patients? Psychother Psychosom 2000, 69: 303–308. 10.1159/000012412PubMedCrossRef Honkalampi K, Hintikka J, Saarinen P, Lehtonen J, Viinamaki H: Is alexithymia a permanent feature in depressed patients? Psychother Psychosom 2000, 69: 303–308. 10.1159/000012412PubMedCrossRef
22.
Zurück zum Zitat Grabe HJ, Spitzer C, Freyberger HJ: Alexithymia and personality in relation to dimensions of psychopathology. Am J Psychiatry 2004, 161: 1299–1301. 10.1176/appi.ajp.161.7.1299PubMedCrossRef Grabe HJ, Spitzer C, Freyberger HJ: Alexithymia and personality in relation to dimensions of psychopathology. Am J Psychiatry 2004, 161: 1299–1301. 10.1176/appi.ajp.161.7.1299PubMedCrossRef
23.
Zurück zum Zitat Luminet O, Rokbani L, Ogez D, Jadoulle V: An evaluation of the absolute and relative stability of alexithymia in women with breast cancer. J Psychosom Res 2007, 62: 641–648. 10.1016/j.jpsychores.2007.01.003PubMedCrossRef Luminet O, Rokbani L, Ogez D, Jadoulle V: An evaluation of the absolute and relative stability of alexithymia in women with breast cancer. J Psychosom Res 2007, 62: 641–648. 10.1016/j.jpsychores.2007.01.003PubMedCrossRef
24.
Zurück zum Zitat Di Schiena R, Luminet O, Philippot P: Adaptive and maladaptive rumination in alexithymia and their relation with depressive symptoms. Pers Individ Dif 2011, 50: 10–14. 10.1016/j.paid.2010.07.037CrossRef Di Schiena R, Luminet O, Philippot P: Adaptive and maladaptive rumination in alexithymia and their relation with depressive symptoms. Pers Individ Dif 2011, 50: 10–14. 10.1016/j.paid.2010.07.037CrossRef
25.
Zurück zum Zitat Pompili M, Di Cosimo D, Innamorati M, Lester D, Tatarelli R, Martelletti P: Psychiatric comorbidity in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide risk. J Headache Pain 2009, 10: 283–290. 10.1007/s10194-009-0134-2PubMedCentralPubMedCrossRef Pompili M, Di Cosimo D, Innamorati M, Lester D, Tatarelli R, Martelletti P: Psychiatric comorbidity in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide risk. J Headache Pain 2009, 10: 283–290. 10.1007/s10194-009-0134-2PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Pompili M, Serafini G, Di Cisimo D, Dominici G, Innamorati M, Lester D, Forte A, Girardi N, De Filippis S, Tatarelli R, Martelletti P: Psychiatric comorbidity and suicide risk in patients with chronic migraine. Neuropsychiatr Dis Treat 2010, 6: 81–91.PubMedCentralPubMedCrossRef Pompili M, Serafini G, Di Cisimo D, Dominici G, Innamorati M, Lester D, Forte A, Girardi N, De Filippis S, Tatarelli R, Martelletti P: Psychiatric comorbidity and suicide risk in patients with chronic migraine. Neuropsychiatr Dis Treat 2010, 6: 81–91.PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Wang S-J: Migraine and suicide. Expert Rev Neurother 2007,7(9):1069–1071. 10.1586/14737175.7.9.1069PubMedCrossRef Wang S-J: Migraine and suicide. Expert Rev Neurother 2007,7(9):1069–1071. 10.1586/14737175.7.9.1069PubMedCrossRef
28.
Zurück zum Zitat Pompili M, Serafini G, Innamorati M, Serra G, Dominici G, Fortes-Lindau J, Pastina M, Telesforo L, Lester D, Girardi P, Tatarelli R, Martelletti P: Patient Outcome in migraine prophylaxis: the role of psychopharmacological agents. Patient Relat Outcome Meas 2010, 1: 107–118.PubMedCentralPubMedCrossRef Pompili M, Serafini G, Innamorati M, Serra G, Dominici G, Fortes-Lindau J, Pastina M, Telesforo L, Lester D, Girardi P, Tatarelli R, Martelletti P: Patient Outcome in migraine prophylaxis: the role of psychopharmacological agents. Patient Relat Outcome Meas 2010, 1: 107–118.PubMedCentralPubMedCrossRef
29.
Zurück zum Zitat Mattila AK, Saarnic SI, Alanen E, Salminen JK, Kronholm E, Jula A, Sintonen H, Joukamaa M: Health-related quality-of-life profiles in nonalexithymic and alexithymic subjects from general population. J Psychosom Res 2010,68(3):279–283. 10.1016/j.jpsychores.2009.09.010PubMedCrossRef Mattila AK, Saarnic SI, Alanen E, Salminen JK, Kronholm E, Jula A, Sintonen H, Joukamaa M: Health-related quality-of-life profiles in nonalexithymic and alexithymic subjects from general population. J Psychosom Res 2010,68(3):279–283. 10.1016/j.jpsychores.2009.09.010PubMedCrossRef
30.
Zurück zum Zitat Modestin J, Furrer R, Malti T: Study on alexithymia in adult nonpatients. J Psychosom Res 2004, 56: 707–709. 10.1016/S0022-3999(03)00125-9PubMedCrossRef Modestin J, Furrer R, Malti T: Study on alexithymia in adult nonpatients. J Psychosom Res 2004, 56: 707–709. 10.1016/S0022-3999(03)00125-9PubMedCrossRef
31.
Zurück zum Zitat Mattila AK, Poutanen O, Koivisto A-M, Salokangas RKR, Joukamaa M: Alexithymia and life satisfaction in primary care patients. Psychosomatics 2007, 48: 523–529. 10.1176/appi.psy.48.6.523PubMedCrossRef Mattila AK, Poutanen O, Koivisto A-M, Salokangas RKR, Joukamaa M: Alexithymia and life satisfaction in primary care patients. Psychosomatics 2007, 48: 523–529. 10.1176/appi.psy.48.6.523PubMedCrossRef
32.
Zurück zum Zitat Grant AM, Franklin J, Langford P: The Self-reflection and Insight Scale: A new measure of private self-consciousness. Soc Behav Pers 2002,30(8):821–836. 10.2224/sbp.2002.30.8.821CrossRef Grant AM, Franklin J, Langford P: The Self-reflection and Insight Scale: A new measure of private self-consciousness. Soc Behav Pers 2002,30(8):821–836. 10.2224/sbp.2002.30.8.821CrossRef
33.
Zurück zum Zitat DaSilveira AC, DeCastro TG, Gomes WG: Escala de Autorreflexão e Insight: nova medida de autoconsciência adaptada e validada para adultos brasileiros. Psico 2012,43(2):155–162. DaSilveira AC, DeCastro TG, Gomes WG: Escala de Autorreflexão e Insight: nova medida de autoconsciência adaptada e validada para adultos brasileiros. Psico 2012,43(2):155–162.
34.
Zurück zum Zitat Masur J, Monteiro M: Validation of the CAGE alcoholism screening test in Brazilian Psychiatry inpatient hospital setting. Braz J Med Biol Res 1983,16(3):215–218.PubMed Masur J, Monteiro M: Validation of the CAGE alcoholism screening test in Brazilian Psychiatry inpatient hospital setting. Braz J Med Biol Res 1983,16(3):215–218.PubMed
35.
Zurück zum Zitat Mari J, Willians PA: A validity study of a psychiatric screening questionnaire (SRQ-20) in primary care in the city of São Paulo. Br J Psychiatry 1986, 148: 23–26. 10.1192/bjp.148.1.23PubMedCrossRef Mari J, Willians PA: A validity study of a psychiatric screening questionnaire (SRQ-20) in primary care in the city of São Paulo. Br J Psychiatry 1986, 148: 23–26. 10.1192/bjp.148.1.23PubMedCrossRef
36.
Zurück zum Zitat Gonçalves DM, Stein AT, Kapczinski F: Avaliação de desempenho do Self-Reporting Questionnaire como instrumento de rastreamento psiquiátrico: um estudo comparativo com o Structured Clinical Interview for DSM-IV-TR. Cad Saude Publica 2008,24(2):380–390. 10.1590/S0102-311X2008000200017PubMedCrossRef Gonçalves DM, Stein AT, Kapczinski F: Avaliação de desempenho do Self-Reporting Questionnaire como instrumento de rastreamento psiquiátrico: um estudo comparativo com o Structured Clinical Interview for DSM-IV-TR. Cad Saude Publica 2008,24(2):380–390. 10.1590/S0102-311X2008000200017PubMedCrossRef
37.
Zurück zum Zitat Taylor GJ, Ryan D, Bagby RM: Toward the development of a new self-report alexithymia scale. Psychother Psychosom 1985, 44: 191–199. 10.1159/000287912PubMedCrossRef Taylor GJ, Ryan D, Bagby RM: Toward the development of a new self-report alexithymia scale. Psychother Psychosom 1985, 44: 191–199. 10.1159/000287912PubMedCrossRef
38.
Zurück zum Zitat Yoshida EMP: Validade da Versão em Português da Toronto Alexithymia Scale-TAS em Amostra Clínica. Psicol Reflex Crit 2007,20(3):389–396. 10.1590/S0102-79722007000300006CrossRef Yoshida EMP: Validade da Versão em Português da Toronto Alexithymia Scale-TAS em Amostra Clínica. Psicol Reflex Crit 2007,20(3):389–396. 10.1590/S0102-79722007000300006CrossRef
39.
Zurück zum Zitat Cunha JA: Manual da versão em português das Escalas Beck. São Paulo: Casa do Psicólogo; 2001. Cunha JA: Manual da versão em português das Escalas Beck. São Paulo: Casa do Psicólogo; 2001.
40.
Zurück zum Zitat Fleck MPA, Louzada S, Xavier M, Chachamovich E, Vieira G, Santos L, Pinzon V: Aplicação da versão em português do instrumento abreviado de avaliação da qualidade de vida “WHOQOL- bref”. Rev Saude Publica 2000,34(2):178–183. 10.1590/S0034-89102000000200012PubMedCrossRef Fleck MPA, Louzada S, Xavier M, Chachamovich E, Vieira G, Santos L, Pinzon V: Aplicação da versão em português do instrumento abreviado de avaliação da qualidade de vida “WHOQOL- bref”. Rev Saude Publica 2000,34(2):178–183. 10.1590/S0034-89102000000200012PubMedCrossRef
41.
Zurück zum Zitat Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J: Reliability of the migraine disability assessment score in a population-based sample of headache suffers. Cephalalgia 1999,19(2):107–114. 10.1046/j.1468-2982.1999.019002107.xPubMedCrossRef Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J: Reliability of the migraine disability assessment score in a population-based sample of headache suffers. Cephalalgia 1999,19(2):107–114. 10.1046/j.1468-2982.1999.019002107.xPubMedCrossRef
42.
Zurück zum Zitat Kokkonen P, Karvonen JT, Veijola J, Läksy K, Jokelainen J, Järvelin MR, Joukamaa M: Prevalence and sociodemographic correlates of alexithymia in a population sample of young adults. Compr Psychiatry 2001,42(6):471–476. 10.1053/comp.2001.27892PubMedCrossRef Kokkonen P, Karvonen JT, Veijola J, Läksy K, Jokelainen J, Järvelin MR, Joukamaa M: Prevalence and sociodemographic correlates of alexithymia in a population sample of young adults. Compr Psychiatry 2001,42(6):471–476. 10.1053/comp.2001.27892PubMedCrossRef
43.
Zurück zum Zitat Joukamaa M, Taanila A, Miettunen J, Karvonen JT, Koskinen M, Veijola J: Epidemiology of alexithymia among adolescents. J Psychosom Res 2007,63(4):373–376. 10.1016/j.jpsychores.2007.01.018PubMedCrossRef Joukamaa M, Taanila A, Miettunen J, Karvonen JT, Koskinen M, Veijola J: Epidemiology of alexithymia among adolescents. J Psychosom Res 2007,63(4):373–376. 10.1016/j.jpsychores.2007.01.018PubMedCrossRef
44.
Zurück zum Zitat Silvia PJ, Phillips AG: Evaluating self-reflection and insight as self-conscious traits. Pers Individ Dif 2011, 50: 234–237. 10.1016/j.paid.2010.09.035CrossRef Silvia PJ, Phillips AG: Evaluating self-reflection and insight as self-conscious traits. Pers Individ Dif 2011, 50: 234–237. 10.1016/j.paid.2010.09.035CrossRef
45.
Zurück zum Zitat Nyklícek I, Vingerhoets JJM: Alexithymia is associated with low tolerance to experimental painful stimulation. Pain 2000, 85: 471–475. 10.1016/S0304-3959(99)00295-XPubMedCrossRef Nyklícek I, Vingerhoets JJM: Alexithymia is associated with low tolerance to experimental painful stimulation. Pain 2000, 85: 471–475. 10.1016/S0304-3959(99)00295-XPubMedCrossRef
46.
Zurück zum Zitat Feldman JM, Lehrer PM, Hochron SM: The predictive value of the Toronto Alexithymia Scale among patients with asthma. J Psychosom Res 2002,53(6):1049–1052. 10.1016/S0022-3999(02)00452-XPubMedCentralPubMedCrossRef Feldman JM, Lehrer PM, Hochron SM: The predictive value of the Toronto Alexithymia Scale among patients with asthma. J Psychosom Res 2002,53(6):1049–1052. 10.1016/S0022-3999(02)00452-XPubMedCentralPubMedCrossRef
47.
Zurück zum Zitat Chugg K, Barton C, Antic R, Crockett A: The impact of alexithymia on asthma patient management and communication with health care providers: a pilot study. J Asthma 2009,46(2):126–129. 10.1080/02770900802468525PubMedCrossRef Chugg K, Barton C, Antic R, Crockett A: The impact of alexithymia on asthma patient management and communication with health care providers: a pilot study. J Asthma 2009,46(2):126–129. 10.1080/02770900802468525PubMedCrossRef
48.
Zurück zum Zitat Topsever P, Filiz TM, Salman S, Sengul A, Sarac E, Topalli R, Gorpelioglu S, Scott YT: Alexithymia in diabetes mellitus. Scott Med J 2006,51(3):15–20. 10.1258/rsmsmj.51.3.15PubMedCrossRef Topsever P, Filiz TM, Salman S, Sengul A, Sarac E, Topalli R, Gorpelioglu S, Scott YT: Alexithymia in diabetes mellitus. Scott Med J 2006,51(3):15–20. 10.1258/rsmsmj.51.3.15PubMedCrossRef
49.
Zurück zum Zitat Consoli SM, Lemogne C, Roch B, Laurent S, Plouin PF, Lane RD: Differences in emotion processing in patients with essential and secondary hypertension. Am J Hypertens 2010,23(5):515–521. 10.1038/ajh.2010.9PubMedCrossRef Consoli SM, Lemogne C, Roch B, Laurent S, Plouin PF, Lane RD: Differences in emotion processing in patients with essential and secondary hypertension. Am J Hypertens 2010,23(5):515–521. 10.1038/ajh.2010.9PubMedCrossRef
50.
Zurück zum Zitat Todarello O, Taylor GJ, Parker JD, Fanelli M: Alexithymia in essential hypertensive and psychiatric outpatients: a comparative study. J Psychosom Res 1995,39(8):987–994. 10.1016/0022-3999(95)00506-4PubMedCrossRef Todarello O, Taylor GJ, Parker JD, Fanelli M: Alexithymia in essential hypertensive and psychiatric outpatients: a comparative study. J Psychosom Res 1995,39(8):987–994. 10.1016/0022-3999(95)00506-4PubMedCrossRef
Metadaten
Titel
Alexithymia and its impact on quality of life in a group of Brazilian women with migraine without aura
verfasst von
Rebeca Veras de Andrade Vieira
Daniel Chaves Vieira
William Barbosa Gomes
Gustavo Gauer
Publikationsdatum
01.12.2013
Verlag
Springer Milan
Erschienen in
The Journal of Headache and Pain / Ausgabe 1/2013
Print ISSN: 1129-2369
Elektronische ISSN: 1129-2377
DOI
https://doi.org/10.1186/1129-2377-14-18

Weitere Artikel der Ausgabe 1/2013

The Journal of Headache and Pain 1/2013 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.